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Abstract
TMPRSS6 is a regulated gene, with a crucial role in the regulation of iron homeostasis by inhibiting hepcidin expression. The
main regulator of iron homeostasis, the antimicrobial peptide hepcidin, which also has a role in immunity, is directly
upregulated by inflammation. In this study, we analyzed whether inflammation is also a modulator of TMPRSS6 expression
in vitro and in vivo and we determined the mechanism of this regulation A Human Hepatoma cell line was treated with
interleukin-6 and mice were injected with lipopolysaccharide and TMPRSS6 expression and the regulatory mechanism were
addressed. In this study, we demonstrate that inflammation downregulates TMPRSS6 expression in vitro and in vivo. The
downregulation of Tmprss6 by inflammation in mice is not dependent on the Bmp-Smad pathway but occurs through a
decrease in Stat5 phosphorylation. Moreover, Stat5 positively regulates Tmprss6 expression directly by binding to a Stat5
element located on the Tmprss6 promoter. Importantly, our results highlight the functional role of inflammatory
modulation of TMPRSS6 expression in the regulation of hepcidin. TMPRSS6 inhibition via decreased STAT5 phosphorylation
may be an additional mechanism by which inflammation stimulates hepcidin expression to regulate iron homeostasis and
immunity.
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Introduction
The transmembrane serine protease matriptase-2, encoded by
the TMPRSS6 gene, is expressed in the liver and is a negative
regulator of hepcidin expression [1]. In humans, mutations in
TMPRSS6 lead to a genetic disorder characterized by an iron
refractory iron deficiency anemia (IRIDA) that is unresponsive to
oral iron treatment but partially responsive to parenteral iron
therapy [2]. The importance of TMPRSS6 in the control of iron
homeostasis and normal erythropoiesis in humans has been
highlighted by genome-wide association studies. These studies
identified common TMPRSS6 variants associated with hemato-
logical parameters and serum iron concentration [3].
Hepcidin is a peptide hormone produced by the liver that
controls iron absorption at the intestinal level, and iron release
from macrophages and hepatocytes. Hepcidin binds to the plasma
membrane iron exporter ferroportin and induces its endocytosis
and proteolysis, preventing release of iron into the plasma [4]. It is
now well established that hepcidin expression is regulated by the
BMP-SMAD pathway in response to iron variation [5]. Mutated
forms of matriptase-2 are unable to cleave membrane hemojuvelin
[6], resulting in a stimulation of the BMP-SMAD signaling
pathway and an inappropriately high hepcidin expression.
Recently, matriptase-2 has been demonstrated to be induced by
acute iron deprivation [7], hypoxia [8], and erythropoietin [9],
and by activators of hepcidin expression such as BMP6 and iron
[10]. It is likely that matriptase-2 is upregulated by these activators
of hepcidin expression as a negative feedback mechanism to
control excessive increases in hepcidin. Thus, matriptase-2 has a
pleiotropic role in hepcidin regulation in response to a number of
stimuli.
Inflammation is a potent stimulator of hepcidin expression. The
upregulation of hepcidin in response to inflammation promotes
hypoferremia through the downregulation of ferroportin iron
export activity. Hepcidin induction has been hypothesized to have
a protective role in infection by sequestering iron from invading
pathogens. As an antimicrobial peptide, hepcidin itself may also
have additional roles in immunity [11].
IL-6 is a major hepatic regulator of the acute-phase response to
inflammatory stimuli including hepcidin induction [12]. IL-6
binding to the IL-6 receptor leads to activation of Janus kinases
that phosphorylate STAT3. Translocation of STAT3 to the
nucleus results in upregulation of hepcidin expression through
STAT3 responsive element on the hepcidin promoter [13]. In
response to inflammatory stimuli, the BMP-SMAD pathway is also
required to activate hepcidin [14], which may involve the
activation of activin B [15].
Although hepcidin expression is induced directly by inflamma-
tory stimuli, we hypothesized that additional fine tuning of its
expression may be required to maintain body iron balance
PLOS ONE | www.plosone.org 1 December 2013 | Volume 8 | Issue 12 | e82127through the regulation of other genes. Specifically, we hypothe-
sized that TMPRSS6 expression could be regulated by inflamma-
tion in order to participate in the regulation of hepcidin. In this
study, we show that TMPRSS6 expression is regulated by
inflammation via STAT5.
Methods
Cell Culture
Hep3B cells (HB-8064, ATCC, Manassas, VA) were cultured in
ATCC-formulated EMEM (ATCC) supplemented with 10% fetal
bovine serum (FBS, ATCC). Hepa1–6 cells (CRL-1830, ATCC)
were cultured in ATCC-formulated DMEM (ATCC) supplement-
ed with 10% fetal bovine serum (FBS, ATCC).
Treatment of Hep3B Cells with IL-6
Hep3B cells (1.2610
5 per well) were seeded onto 24-well plates.
Twenty-four hours later, the culture medium was switched to 1%
FBS medium. After 7 hours, cells were treated with recombinant
human IL-6 (5, 20, 100 ng/mL, 16 h) (R&D Systems) and then
harvested for RNA extraction.
Regarding matriptase-2 activity, after 7 hours, culture medium
was replaced with Optimem media (Invitrogen, Carlsbad, CA) and
cells were treated with recombinant human IL-6 (20 ng/mL) for
16 hours. Matriptase-2 activity was assayed as previously described
[10].
Animals
The Institutional Animal Care and Use Committee at the
Massachusetts General Hospital (MGH) approved all of the
following animal protocols.
Eight-week-old male C57BL/6 mice received four intraperito-
neal injections of recombinant mouse IL-6 (406-ML, R&D
systems, Minneapolis, MN) in PBS at 25 mg/k (one injection
every 3 hours). (N=5 per group). Mice were sacrificed and tissues
harvested for analysis three hours after the last injection.
Figure 1. Tmprss6 expression is down-regulated by inflammation. (A–B) Hep3B cells were treated with IL-6 for 16 hours and were analyzed
for HAMP and TMPRSS6 relative to RPL19 mRNA expression. For each experiment, raw data were normalized to the value of the non-treated group.
Values shown are means of normalized expression values for 4–7experiments+/2 SEM. Means in treated groups were compared to 1 by one sample
student t tests. (C) 15 mg of protein from conditioned media of Hep3B cells treated with IL-6 (20 ng/mL) for 16 hours were used to measure the
matriptase-2 activity. Activities were measured in duplicate in 4 independent experiments. Values shown are mean of activities divided by a activities
calibrator quantity (the mean value of activity for the control group)+/2 SEM. Mean in control and treated groups were compared by student t tests.
(D) Mice received 4 intraperitoneal injections of recombinant mouse IL-6 and were sacrificed 3 hours after the last injection. Tmprss6 relative to Rpl19
mRNA expression was analyzed by quantitative real-time RT- PCR. Values shown are means of expression values divided by a calibrator quantity (the
mean value of expression for the baseline group)+/2 SEM. Means in baseline and treated groups were compared by student t tests. (E–F) Mice
received one injection of LPS (n=5 per group) and were sacrificed 6, 16 and 24 hours after injection. Hamp and Tmprss6 relative to Rpl19 mRNA
expression were analyzed by quantitative real-time RT- PCR. Values shown are means of expression values divided by a calibrator quantity (the mean
value of expression for the baseline group)+/2 SEM. Means in baseline and treated groups were compared by student t tests. p values p,0.05 were
considered statistically significant. Significances are: *p,0.05; **p,0.01; ***p,0.005; ****p,0.001.
doi:10.1371/journal.pone.0082127.g001
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Germantown, NY) received an intraperitoneal injection of LPS
diluted in PBS at 1 mg/g body weight (serotype 055:B5, Sigma,
Allentown, PA) (n=5 per group). Mice were sacrificed and tissues
harvested for analysis at 6, 16, and 24 hours after injection.
8-week-old males Hjv
2/2 mice on a C57BL/6J background, or
wild-type littermate received an intraperitoneal injection of LPS
diluted in PBS at 1 mg/g body weight (Sigma) (n=5 per group).
Mice were sacrificed and tissues harvested for analysis 6 hours
after injection.
RNA Extraction and Quantitative Real-time PCR
Total RNA and quantitative real-time RT-PCR were prepared
as previously described [10]. TMPRSS6, HAMP and RPL19
transcripts were amplified with specific primers (Table S1).
Western-blot Analysis
Nuclear proteins were extracted from mice livers with NE-PER
Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific,
Rockford, IL). Equal amounts of protein were subjected to SDS-
PAGE and transferred to PVDF Membrane (Biorad). For p-
SMAD1-5-8, membranes were blocked with stringent milk buffer
[5] 1 hour RT and then incubated overnight 4uC with rabbit anti-
Phospho-Smad1 (Ser463/465)/Smad5 (Ser463/465)/Smad8
(Ser426/428) (1:500, Cell Signaling, Beverly, MA). For p-Stat5,
membranes were incubated in blocking buffer (5% milk, 0.1%
Tween20, 16PBS), 1 hour RT and then incubated overnight 4uC
with rabbit anti-Phospho-Stat5 (Tyr694) (1:1000, Cell Signaling).
All blots were washed with PBST (0.1% Tween20, 16PBS) and
then incubated for 1 hour at RT with Anti-rabbit IgG, HRP-
linked Antibody (1:2000, Cell Signaling) in 5% milk PBST and
developed using a chemiluminescence (ECL, PerkinElmer, Wal-
tham, MA). Protein loading was controlled with Anti-TBP
antibody. Chemiluminescence was quantified with IPLab imaging
software (BD Biosciences).
Electrophoretic Mobility Shift Assay (EMSA)
The Li-Cor EMSA buffer kit (Li-Cor, Lincoln, NE) was used
according to the manufacturer’s instructions. Infrared (IR) labeled
custom oligos specifics for the STAT5 element from mouse
Tmprss6 promoter were ordered from Integrated DNA Technol-
ogies (Coralville, IA).
A total of 5 mg of nuclear protein extract was incubated with
2.5 nM of labeled oligos, 16binding buffer, Poly (dl?dC) 1 mg/mL
(in 10 mM Tris, 1 mM EDTA, pH 7.5), 25 mM DTT/2.5%
Tween-20, 1% NP-40, 100 mM MgCl2, and 4% Ficoll for 30
minutes at room temperature shielded from light. DNA/protein
complexes were visualized on a native 4–12% Tris-Borate-EDTA
polyacrylamide gel (Invitrogen). Gels were immediately removed
from cassettes and scanned using the Odyssey.
For WEMSA experiments, after EMSA, nucleic acids and
bound proteins were transferred onto nitrocellulose membrane
(Invitrogen). Blots were blocked with 5% milk PBST 1 hour RT,
and incubated overnight at 4uC with rabbit anti-STAT5 antibody
Figure 2. TMPRSS6 downregulation by inflammation is not dependent on the BMP-SMAD pathway. (A) Liver nucleic lysates from mice
were analyzed by Western blot for p-Smad1-5-8 relative to TBP. Values shown are means of expression values divided by a calibrator quantity (the
mean value of expression for the baseline group)+/2 SEM. Means in baseline and treated groups were compared by student t tests. (B) WT and Hjv
2/
2 littermate mice were injected with LPS (n=4 per group) and sacrificed 6 hours later. Tmprss6 relative to Rpl1 9 mRNA expression was analyzed by
quantitative real-time RT- PCR. Values shown are means of expression values divided by a calibrator quantity (the mean value of expression for the
mock group)+/2 SEM. Means in mock and treated groups were compared by student t tests. P values p,0.05 were considered statistically significant.
Significances are: *p,0.05; ***p,0.005.
doi:10.1371/journal.pone.0082127.g002
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milk PBST. After washing with PBST 0.1%, blots were incubated
for 1 hour at RT with Anti-rabbit IgG, HRP-linked Antibody
(1:2000, Cell Signaling) in 5% milk PBST and developed using a
chemiluminescence (ECL, PerkinElmer).
Figure 3. TMPRSS6 downregulation by inflammation is mediated by p-Stat5. (A) Liver nucleic lysates from mice were analyzed by Western
blot for p-Stat5 relative to TBP. Values shown are means of expression values divided by a calibrator quantity (the mean value of expression for the
baseline group)+/2 SEM. Means in baseline and treated groups were compared by student t tests. (B) Hepatic nuclear extracts from mice at Baseline
or 16 hrs after injection with LPS (n=4 per group) were subjected to EMSA using a Stat5 binding sequence from the mouse Tmprss6 promoter (left
panel). Nucleic acids and bound proteins were transferred on membrane and analyzed by Western blot for Stat5. Stat5 shift was quantified using Li-
Cor software. (C) Livers from Baseline mice (n=5) were subjected to ChIP with Stat5 antibody and normal IgG antibody. Recovered DNA was analyzed
for the presence of TMPRSS6 promoter. P values p,0.05 were considered statistically significant. Significances are: *p,0.05; ***p,0.005.
doi:10.1371/journal.pone.0082127.g003
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Chromatin immunoprecipitation was performed on the liver of
8-week-old C57BL/6 males (baseline) using SimpleChIP Plus
Enzymatic Chromatin IP Kit (Cell Signaling) according to the
manufacturer’s instructions. Briefly, tissues were fixed with 1.5%
formaldehyde for 20 minutes. DNA was sonicated using a Misonix
XL Sonicator Ultrasonic Cell Processor (power, 40%; 3620
seconds). DNA fragments were recovered using rabbit anti-Stat5
(Santa-Cruz Biotechnology) or normal rabbit anti-IgG. Recovered
DNA fragments were directly used for quantitative real-time PCR
analysis with specific primers (Table S1) for the region of the
mouse Tmprss6 promoter containing the STAT5 element.
SiRNA Experiments
Hep3B cells (1.2610
5 per well) were seeded onto 24-well plates.
During seeding, cells were reverse-transfected with 1 mlo f
lipofectamine 2000 (Invitrogen) and siRNA control (ON-TAR-
GET plus Non-targeting pool D-001810-10-05, Dharmacon,
Chicago, IL) or human STAT5b (siGENOME SMART pool
siRNA M-010539-02-0005, Dharmacon) or human TMPRSS6
(siGENOME SMART pool siRNA D-006052, Dharmacon). Five
hours later, the transfection media was replaced with culture
medium to stop the transfection.
Figure 4. Stat5 regulates Tmprss6 expression and this participates to the regulation of hepcidin expression by IL-6 treatment. (A)
Hepa 1–6 cells were transfected with mouse wild-type or mutant Tmprss6 promoter-luciferase construct, in presence of empty vector or Stat5b
plasmid. After 48 hours, luciferase activity was determined. The assay was performed in duplicate for a total of 6 independent experiments. For each
experiment, raw data were normalized to the value of luciferase activity in cells transfected with the empty vector. Values shown are mean of
normalized luciferase activities+/2 SEM. Mean in treated groups was compared to 1 by one sample student t tests. (B) Hep3B cells were transfected
with siRNA control or siRNA Stat5b and analyzed for TMPRSS6 relative to RPLl19 mRNA expression. For each experiment, raw data were normalized to
the expression value in mock-treated cells. Values shown are means of normalized expression values obtained in 3 independent experiments+/2
SEM. Means in siRNA control and siRNA STAT5b groups were compared by student t tests. (C) Hep3B cells were transfected with siRNA control or
siRNA TMPRSS6 and treated without or with 20 ng/mL of IL-6, followed by analysis of HAMP relative to RPL19 mRNA expression. The mean 4
independent experiments is presented. Values shown are means of expression values divided by a calibrator quantity (the mean value of expression
for the cells transfected with siRNA control non-treated with IL-6)+/2 SEM. Means in non-treated and IL-6 treated groups were compared by student t
tests. (D) Hep3B cells were transfected with human HAMP promoter-luciferase construct in combination with either empty vector or human TMPRSS6
plasmid. Thirty-two hours after transfection, cells were treated without or with 20 ng/ml of IL-6. After 16 hours of IL-6 treatment, luciferase activity
was determined. The assay was performed in duplicate for a total of 6 independent experiments. Values shown are means of luciferase activity
divided by a calibrator quantity (the mean value of luminescence for the mock non-treated with IL-6)+/2 SEM. Means in non-treated and IL-6 treated
groups were compared by student t tests. P values p,0.05 were considered statistically significant. Significances are: *p,0.05.
doi:10.1371/journal.pone.0082127.g004
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with FBS 1% medium then harvested for RNA extraction 24
hours later.
For TMPRSS6 silencing, 24 hours later, cells were serum
starved with FBS 1% medium and 7 hours later treated with IL-6
(20 ng/mL, R&D Systems) and harvested for RNA extraction 48
hours after treatment.
Luciferase Assay
Mouse Tmprss6 promoter was generated by amplifying 300 ng
mouse genomic DNA (C57BL/6) using primers listed in Table S1.
The resulting PCR fragment was inserted into the pGl3-promoter
vector (Promega, Madison, WI). The STAT5 mutation construct
was generated with QuikChange Site-Directed Mutagenesis Kit
(Stratagene, La Jolla, CA, USA) using the primers presented in
Table S1. Hepa 1–6 cells (1.2610
5 per well) were seeded onto 24-
well plates and transfected 24 hours later for 5 hours with mouse
Tmprss6 wt-luc vector or mouse Tmprss6 mt-luc vector (250 ng),
pRL-TK (25 ng) and 200 ng of pcDNA empty vector or mouse
Stat5b vector with 2 ml of lipofectamine 2000 (Invitrogen) in
Optimem media. After 24 hours, cells were serum starved with 1%
FBS media for 24 hours and cell lysates were prepared with 1X
passive lysis buffer (Promega). Luciferase activity was determined
with Dual-LuciferaseH Reporter Assay System (Promega) accord-
ing to manufacturer’s directions. The assay was performed in
duplicate for each experiment. Our results were reported as RLU
(relative light units).
Statistics
For each quantitative variable (mRNA expression, protein level,
matriptase 2 activity, luciferase activity), individual values were
divided by a calibrator quantity, which was the mean value of this
variable for the control group (baseline, mock, control). Means+/
2 SEM of the calibrated values obtained within each group are
shown on the different figures. Calibrated values in two groups
(control/treated) were compared by Student t tests.
For experiments figures 1A, 1B, 4A, 4B, S1 and S6, raw data
were normalized to the value of the non-treated control. Means in
treated groups were compared to 1 by one sample student t tests.
Results
TMPRSS6 mRNA Expression is Decreased Acutely by IL-6
Treatment in vitro
To test whether IL-6 treatment could modulate TMPRSS6
mRNA expression in vitro, human hepatoma-derived Hep3B cells
were treated with increasing doses of IL-6, and then HAMP and
TMPRSS6 mRNA expression was evaluated by quantitative real-
time PCR. Treatment with IL-6 induced a dose-dependent
increase of HAMP mRNA expression (from 2.4 with 5 ng/mL to
5.3-fold with 100 ng/mL) (Figure 1A). In contrast, TMPRSS6
mRNA was significantly decreased by IL-6 treatment in a dose
dependent manner (from 18% with 5 ng/mL to 60% with
100 ng/mL) (Figure 1B). The ability of IL-6 to decrease
TMPRSS6 expression was also demonstrated in another human
hepatoma-derived cell line, HepG2 cells (Figure S1A–B).
Figure 5. Schematic representation showing proposed role of TMPRSS6 regulation by inflammation via STAT5. We propose that in
addition to being stimulated by several signals that regulate hepcidin such as iron, BMP6, erythropoeitic drive, and hypoxia, TMPRSS6 expression is
also inhibited indirectly by IL-6. IL-6 stimulates hepcidin expression through the induction of STAT3 phosphorylation and through the stimulation of
the BMP6-HJV-SMAD pathway activity, leading to binding of p-STAT3 on STAT3-responsive element (STAT3-RE) and SMAD complexes to BMP-
responsive elements (BMP-REs) on the hepcidin promoter. In parallel, inflammation through IL-6 and/or through another non-identified cytokine,
inhibits the STAT5 phosphorylation leading to a decrease of P-STAT5 binding on the STAT5-responsive element (STAT5-RE) of the TMPRSS6 promoter
resulting in a decrease of TMPRSS6 expression. TMPRSS6 is a negative feedback inhibitor of BMP-SMAD pathway activity and hepcidin expression by
cleaving the BMP co-receptor HJV. By inhibiting this negative feedback, TMPRSS6 participates to the hepcidin increase in response to IL-6.
doi:10.1371/journal.pone.0082127.g005
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expression induced by IL-6 treatment was functionally relevant,
we measured matriptase-2 activity in conditioned media derived
from Hep3B cells treated with IL-6. Treatment with 20 ng/mL of
IL-6 lowered matriptase-2 activity by 30% in conditioned media
(Figure 1C). The specificity of the assay for matriptase-2 protease
activity was previously demonstrated [10]. These results indicate
that in vitro, IL-6 downregulates TMPRSS6 mRNA expression and
leads to a decrease of matriptase-2 activity.
TMPRSS6 mRNA Expression is Decreased Acutely by
Inflammation in vivo
Next, we investigated whether Il-6 could regulate Tmprss6
mRNA expression in vivo. Mice received four injections (every
three hours) of 25 mg/kg of Il-6 and hepatic Tmprss6 mRNA
expression was measured 3 hours after the last injection.
Compared to baseline mice, Il-6 injected-mice had a significant
downregulation of liver Tmprss6 mRNA level by 40% (Figure 1D).
This result shows that the downregulation of Tmprss6 mRNA
expression by IL-6 seen in vitro also occurs in vivo.
Since injection of IL-6 had just a short-term effect onTmprss6
mRNA expression in vivo, possibly related to rapid clearance of
injected Il-6, we tested whether Tmprss6 mRNA expression was
modulated in an inflammation model where IL-6 was highly
induced. Mice were injected with 1 mg/g body weight of
lipopolysaccharide (LPS), a potent inducer of inflammation [16].
The presence of an inflammatory state was established by the
measurement of acute-phase genes Crp and Il-6 in LPS-treated
mice (Figure S2). LPS injection lead to a significant increase in
hepatic Hamp mRNA by 4-fold at 6 hours after injection compared
to baseline mice, returning to the basal level 24 hours after
injection (Figure 1E). Importantly, as partially reported during the
preparation of this manuscript [17], LPS injection significantly
decreased Tmprss6 mRNA expression with a maximal reduction of
64% at 16 hours after injection (Figure 1F) compared to baseline
mice. These results indicate that Tmprss6 mRNA expression is
decreased acutely by inflammation in vivo, at least in part via Il-6.
Inflammation Regulates Tmprss6 mRNA Expression
Through Stat5
Because Tmprss6 mRNA expression is regulated by the Bmp-
Smad pathway [10], we investigated whether the Bmp-Smad
pathway was also involved in the regulation of Tmprss6 mRNA
expression by inflammation. In wild-type mice, injection of LPS
induced a trend toward decreased phosphorylation of Smad1-5-8
protein by 50% 6 hours after injection, and a return to baseline
levels 16 hours after injection (Figure 2A). These results suggest
only a partial temporal correlation between Bmp-Smad pathway
activity and Tmprss6 mRNA regulation by inflammation. To
further explore a causative role for the BMP-SMAD pathway, we
injected LPS into Hjv
2/2 mice, where the Bmp-Smad pathway is
inhibited [18]. Similar to the results obtained in wild-type
littermate mice, injection of LPS in Hjv
2/2 mice lead to a similar
downregulation of Tmprss6 mRNA expression by 57%, indicating
that an intact Bmp-Smad pathway is not required for the
regulation of Tmprss6 expression by inflammation (Figure 2B).
Because inflammation modulates Hamp expression via the
phosphorylation of Stat3 we investigated the regulation of p-Stat3
in the liver in response to LPS injection. Six hours after LPS
injection, Stat3 phosphorylation was strongly increased and then
progressively returned to baseline (Figure S3). These results show
that the regulatory time-course of Tmprss6 mRNA expression and
p-Stat3 levels are different, indicating that p-Stat3 probably does
not regulate Tmprss6 mRNA expression.
To further explore the mechanism of Tmprss6 mRNA regulation
by inflammation, we ran a computational analysis of the mouse
Tmprss6 gene promoter with Genomatix Software Suite. We
identified one canonical Stat5 DNA-binding site (TTCN3GAA) in
position 2327 upstream of exon 1, conserved inter-species (Figure
S4). We therefore evaluated the Stat5 phosphorylation level in
liver nuclear extracts of wild-type mice injected with LPS.
Injection of LPS induced a strong decrease of Stat5 phosphory-
lation 6 hours after LPS injection (by 50%), with a maximal
decrease 16 hours after LPS injection by 87% (Figure 3A)
compared to baseline mice, correlating with the decrease of
Tmprss6 mRNA expression.
To determine whether the Tmprss6 gene promoter is a direct
target of Stat5, we performed an electrophoretic mobility shift
assay (EMSA) with a specific labeled probe containing the Stat5
element of the Tmprss6 gene promoter. Compared to the migration
of the free labeled probes in absence of nuclear extract (Figure 3B,
left panel, lane 1), incubation with nuclear extracts from baseline
mice induced a shift in migration, indicating protein binding on
the Stat5 element of the Tmprss6 gene promoter (Figure 3B, left
panel, lane 2–5). Interestingly, 16 hours after LPS injection, when
the Stat5 phosphorylation level was reduced (Figure 3A), the shift
in migration was decreased by 60% (Figure 3B, left panel, lane 6–
9). To confirm that Stat5 proteins were responsible for the shift in
migration, we used a Combined Western Blotting Electrophoresis
Mobility Shift Assay (WEMSA). After EMSA, bound proteins
were transferred to a nitrocellulose membrane and immunoblotted
with a STAT5 specific antibody. No signal was detected in the
absence of nuclear extract (Figure 3B, right panel, lane 1). We
were able to detect a single specific band at the same size as the
shifted complex of the EMSA experiment (figure 3B, right panel).
Moreover, the intensity of the signal corresponding to the binding
of the STAT5 antibody was stronger when the nuclear extracts
were prepared from liver of baseline mice (Figure 3B, right panel,
lane 2–5) compared to nuclear extracts prepared from liver of
mice injected with LPS for 16 hours (Figure 3B, right panel, lane
6–9). These results indicate that the EMSA complex contained
Stat5 proteins bound to the Stat5 element on the Tmprss6
promoter.
To test whether Stat5 recognizes this DNA-binding site in the
Tmprss6 promoter in vivo, we performed chromatin-immunopre-
cipitation (ChIP) experiments using Stat5 antibody on the liver of
baseline mice. Quantitative real-time PCR analysis of immuno-
precipitated Stat5-DNA complexes yielded the amplification of a
PCR product representing Stat5-binding sites in the Tmprss6
promoter in specific Stat5 ChIP, but lower in control IgG ChIP
experiments (Figure 3C).
To verify a functional role for Stat5 binding to the mouse
Tmprss6 promoter on Tmprss6 mRNA expression, we studied the
effect of Stat5 overexpression on Tmprss6 promoter activity in vitro
using a mouse Tmprss6 promoter luciferase construct (Tmprss6 wt-
Luc) in a mouse hepatoma cell line (hepa 1–6 cells) since this
construct was not functional in the human cell line Hep3B (data
not shown). Tmprss6 wt-Luc was transfected in presence of an equal
quantity of empty plasmid or construct encoding a mouse Stat5b
(major form of STAT5 expressed in hepatocytes), and relative
luciferase activity was measured 48 hours after transfection.
Transfection of mStat5b led to a significant increase of total Stat5
protein (Figure S5A). mStat5b overexpression significantly in-
creased Tmprss6 promoter luciferase activity by 1.55 fold
compared to empty vector (Figure 4A, black bars), confirming
that Stat5 is a positive regulator of Tmprss6 gene expression. Next,
Regulation of TMPRSS6 Expression by Inflammation
PLOS ONE | www.plosone.org 7 December 2013 | Volume 8 | Issue 12 | e82127we mutated the palindromic half-site of the predicted mStat5
element on the Tmprss6-Luc construct (Tmprss6 mt-Luc), a
mutation that is sufficient to completely inhibit the binding of
Stat5. This mutation reduced the increase of Tmprss6 promoter
activity induced by mStat5b overexpression by 50% (Figure 4A,
gray bars), indicating that Stat5 regulates Tmprss6 expression, at
least in part, by directly binding its promoter. In addition to the
binding of STAT5 on the perfect site TTCN3GAA, STAT5
transcription factors can also bind to related homologous sites such
as the STAT6 binding sequence TTCN4GAA [19]. Indeed, we
identified with the Genomatix software suite three Stat6 binding
sequences in the mouse Tmprss6 promoter that could explain the
residual mTmprss6 promoter activity in response to Stat5
expression. In vivo, the non-binding of STAT5 transcription factor
on the sequence TTCN4GAA is regulated by the chromatin
conformation [19] that can be loosened on the Tmprss6-luc vector.
To further support the role of STAT5 in the regulation of
TMPRSS6 mRNA expression, we tested the effects of siRNA-
mediated knockdown of STAT5b on TMPRSS6 mRNA expres-
sion in Hep3B cells. Transfection with siRNA STAT5b decreased
STAT5b mRNA expression by 67% (Figure S5B). Importantly,
silencing STAT5b induced a significant downregulation of
TMPRSS6 mRNA expression by 30% compared to Hep3B cells
transfected with siRNA control (Figure 4B). Together, these results
reinforce the hypothesis that STAT5 is a positive regulator of
TMPRSS6 expression. Interestingly, the silencing of STAT5b
mRNA expression results also in a significant increase of HAMP
mRNA expression by 1.25 fold (Figure S5C) similar to the increase
induced by the silencing of TMPRSS6 mRNA expression in non-
treated cells (Figure 4C).
Regulation of TMPRSS6 Expression by Inflammation has a
Functional Role in Hepcidin Modulation
To characterize the functional role of TMPRSS6 downregula-
tion in the upregulation of hepcidin by inflammation, we
transfected Hep3B cells with siRNA TMPRSS6 [10] followed by
treatment with 20 ng of IL-6 for 48 hours and measurement of
HAMP mRNA expression. Forty-eight hours corresponds to a time
point where TMPRSS6 mRNA expression is no longer inhibited by
IL-6 treatment (Figure S6). Inhibition of TMPRSS6 mRNA
expression allowed a significantly higher increase of HAMP
mRNA expression in response to IL-6 treatment after 48 hours
by 2-fold compared to Hep3B cells transfected with siRNA control
(Figure 4C).
We next performed the converse experiment by transfecting
Hep3B cells with human HAMP promoter/firefly luciferase
reporter construct in the presence of an equal quantity of empty
plasmid or a construct encoding human matriptase-2 [10].
Transfected Hep3B cells were treated with IL-6 for 16 hours
and luciferase activity was measured. Treatment with IL-6
induced an increase of the HAMP promoter/firefly luciferase
activity by 7.7 fold (Figure 4D). Over-expression of human
matriptase-2 significantly prevented this increase and reduced the
IL-6 mediated stimulation of HAMP promoter/firefly luciferase
activity by 52% (Figure 4D). Together, these results indicate that,
in vitro, the decrease of TMPRSS6 mRNA expression induced by
inflammation participates in the upregulation of hepcidin expres-
sion.
Discussion
Inflammation due to infection, autoimmune disease, or cancer
stimulates the production of many proinflammatory cytokines such
as IL-6, leading to increased hepcidin expression. However, the
antimicrobial and immune modulating properties of hepcidin need
to be balanced with its role in controlling the availability of iron.
Thus, hepcidin expression during inflammation needs to be finely
regulated. Here, we identified a novel pathway for hepcidin
regulation by inflammation via TMPRSS6 and STAT5 that is
independent of the previously described STAT3 and BMP-SMAD
pathways.
In this study, we demonstrated that treatment of a hepatoma
cell line with IL-6 or injection of IL-6 or LPS in mice decreased
TMPRSS6 mRNA expression. The reduced potency of IL-6
compared with LPS to suppress TMPRSS6 mRNA suggests that
LPS may regulate TMPRSS6 through other mechanisms in
addition to IL-6, similar what has been reported for hepcidin [15].
We also characterized the mechanism of TMPRSS6 regulation by
inflammation. We provided several lines of evidence showing that
inflammation downregulates Tmprss6 via decreasing Stat5 phos-
phorylation. STAT5a/b are transcription factors regulated by a
wide variety of cytokines such as interleukins. Importantly,
consistent with the results in our study, published literature shows
that in response to turpentine-induced inflammation in rats,
Stat5b protein level is reduced in the nucleus of the liver 12 hours
after injection [20]. The mechanism(s) by which inflammatory
cytokines decrease Stat5 signaling remain to be elucidated.
Global Stat5a/b
2/2 and hematopoietic-specific Stat5a/b
2/2
mice have a severe microcytic hypochromic anemia that is
proposed to be related to the lack of Stat5 binding to the promoter
of Irp2 and Tfr1, leading to the inhibition of iron uptake in
erythroid cells [21]. Interestingly, global Stat5a/b
2/2 mice have a
more severe microcytic hypochromic anemia than hematopoietic-
specific Stat5a/b
2/2 mice, suggesting that the role of Stat5 in other
cell types may contribute to the severity of the microcytic
hypochromic anemia. Indeed, Stat5 seems to regulate the
transcription of many other genes involved in iron metabolism,
including TMPRSS6 as demonstrated in our study. Conditional
knockout of Stat5 in other cell types including hepatocytes will be
relevant to characterize a more complete role of Stat5 in iron
metabolism.
TMPRSS6 expression is stimulated by EPO, [9] that is a positive
regulator of STAT5-phosphorylation [22] and a negative regula-
tor of hepcidin expression [23]. Since we identified in this study
that Stat5 is a positive regulator of Tmprss6 expression, it can be
hypothesize that an upregulation of STAT5-phosphorylation and
consequent TMPRSS6 induction by EPO injection may play a
role in the regulatory mechanism leading to the hepcidin decrease
in response to EPO. Further studies will be required to address this
possible role.
In a recent study published by Nai et al [24], the authors
highlighted that in a mouse model of b-thalassemia (Hbb
th3/+
mice), serum EPO level is elevated, Hamp mRNA expression in the
liver is decreased, and Id1 and Tmprss6 mRNA expression in the
liver are upregulated. Since ID1 is a positive regulator of
TMPRSS6 expression [10], the authors suggested that the
upregulation of Tmprss6 mRNA expression seen in Hbb
th3/+ mice
is induced by the upregulation of Id1 expression. Here, we
demonstrated that in addition to ID1, STAT5 is also a positive
regulator of TMPRSS6 expression. Since EPO is increased in
Hbb
th3/+ mice, we hypothesize that an upregulation of Stat5-
phophorylation by EPO could also be involved in Tmprss6
upregulation seen in Hbb
th3/+ mice.
Our results suggest that inflammation regulates TMPRSS6
expression, and in turn TMPRSS6 has a functional role on
hepcidin regulation under inflammation conditions. Hepcidin
regulation by inflammation is known to occur through the IL6/
STAT3 [13] pathway but also through the BMP-SMAD pathway
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current work highlights an additional regulatory mechanism
through IL-6 involving matriptase-2 (Figure 5). Determining what
is the exact responsibility in vivo of each regulatory mechanism
involved in hepcidin modulation by inflammation is challenging
since both STAT3 and BMP-SMAD pathway are required [14].
However, it is clear that all of these mechanisms have the ability to
independently regulate hepcidin expression [12,13,15]. In our LPS
injected mice cohort, the hepcidin level peaks after 6 hrs, whereas
activin B peaks at 4 hrs (Figure 1 and Figure S7). Although
TMPRSS6 is maximally decreased after 16 hrs, it is already
significantly decreased by 6 hrs, and in fact levels at 16 hrs were
not significantly different from 6 hrs. In addition, LPS induces the
highest acute STAT3 phosphorylation before the hepcidin peak
[15]. The fact that none of the known regulatory mechanism has
exactly the same time-course than hepcidin in response to
inflammation leads to the hypothesis that the hepcidin level peak
may results from the combination of all the regulatory mechanisms
at 6 hrs after LPS injection (i.e. low TMPRSS6 level, high
STAT3-phosphorylation, and high activin B level). Indeed, this
multi-layered regulatory mechanism is consistent with a fine-
tuning of hepcidin expression in response to inflammation.
Chronic inflammation and the consequent increase of hepcidin
are responsible for anemia of chronic diseases (ACD) [25].
Currently available treatment strategies for ACD have limited
success and can increase risk of infections, mortality, iron overload
[26]. New therapeutic strategies are currently being developed in
order to target the hepcidin axis and decrease hepcidin production
such as BMP-SMAD pathway inhibitors [27]. Since we have
demonstrated that TMPRSS6 expression is downregulated by
inflammation, and TMPRSS6 is a known inhibitor of hepcidin
expression, our results suggest that stimulating TMPRSS6
expression in patients with ACD could be another approach to
prevent the hepcidin over-expression seen in ACD.
In summary, we demonstrate here that TMPRSS6 is regulated
by inflammation and has a functional role in regulating hepcidin
expression in this setting (Figure 5). We also show for the first time
that in addition to its role on Irp2 and Tfr1 expression, Stat5
regulates Tmprss6 (Figure 5), emphasizing the important role of
Stat5 in iron metabolism. Understanding the mechanism and the
role of inflammation on TMPRSS6 regulation may ultimately lead
to new therapeutic strategies to treat diseases where hepcidin levels
are deregulated such as b-thalassemia and anemia of chronic
disease.
Supporting Information
Figure S1 (A–B) HepG2 cells were treated with 100 ng/mL of
IL-6 for 16 hours and were analyzed for HAMP and TMPRSS6
relative to RPL19 mRNA expression by quantitative real-time RT-
PCR. For each experiment, raw data were normalized to the
expression value in the control group. Values shown are means of
normalized expression values in 4 independent experiments+/2
SEM. Means in IL-6 treated cells were compared to one by one
sample student t tests. *p,0.05.
(TIF)
Figure S2 Eight-week-old male C57BL/6 mice received one
intraperitoneal injection of LPS 1 mg/g body weight (n=5 per
group) and were sacrificed 6, 16 and 24 hours after injection. Crp
and Il-6 relative to Rpl19 mRNA expression were analyzed by
quantitative real-time RT- PCR. Values shown are means of
expression values divided by a calibrator quantity (the mean value
of expression for the baseline group)+/2 SEM. Means in baseline
and treated groups were compared by student t tests. ***p,0.005;
****p,0.001.
(TIF)
Figure S3 Liver nucleic lysates from baseline mice and mice
injected with LPS were used to measure the p-Stat3 protein level.
4 mg of proteins were subjected to western-blot analysis with rabbit
anti-p-Stat3 (1:1000, Cell Signaling). Membrane was stripped with
and reprobed with TBP antibody (1/1000). Values shown are
means of expression values divided by a calibrator quantity (the
mean value of expression for the baseline group)+/2 SEM. Means
in baseline and treated groups were compared by student t tests.
***p,0.005; ****p,0.001.
(TIF)
Figure S4 Promoter analysis for transcription binding sites was
run with Genomatix Software Suite and indicate the presence of
STAT5 binding sequence in the TMPRSS6 promoter in Mouse,
Rat and Human.
(TIF)
Figure S5 (A) Cell lysates prepared with 1X passive lysis buffer
for the luciferase experiment were used to measure the Stat5
protein level. 10 mg of proteins were subjected to western-blot
analysis with rabbit anti-Stat5 (1:1000, Santa-cruz). Membrane
was stripped with and reprobed with Actin antibody (1/10000)
(B,C) Hep3B cells were reverse-transfected with 10 nM of control
siRNA or human STAT5b. Five hours later, the transfection
media was replaced with culture medium to stop the transfection.
Twenty-four hours later, cells were serum starved with FBS 1%
medium then harvested for RNA extraction 24 hours later. Stat5b
and HAMP relative to RPL19 mRNA expression were analyzed by
quantitative real-time RT- PCR. Values shown are means of
expression values divided by a calibrator quantity (the mean value
of expression for the mock)+/2 SEM. Means in siRNA control
and siRNA STAT5b groups were compared by student t tests.
*p,0.05; ****p,0.001.
(TIF)
Figure S6 Hep3B cells were treated with 20 ng/mL of IL-6 for
several time points between 1 and 48 hours and were analyzed for
TMPRSS6 relative to RPL19 mRNA expression by quantitative
real-time RT- PCR. For each experiment, raw data were
normalized to the expression value of the non-treated cells. Values
shown are means of normalized expression values in 6 indepen-
dent experiments+/2 SEM. Means in IL-6 treated groups were
compared to 1 by one-sample student t tests. *p,0.05.
(TIF)
Figure S7 (A) Eight-week-old male C57BL/6 mice received one
intraperitoneal injection of LPS 1 mg/g body weight (n=5 per
group) and were sacrificed 4, 6, 16 and 24 hours after injection.
Inhbb relative to Rpl19 mRNA expression was analyzed by
quantitative real-time RT- PCR. Values shown are means of
expression values divided by a calibrator quantity (the mean value
of expression for the baseline group)+/2 SEM. Means in baseline
and treated groups were compared by student t tests. (B,C) Eight-
week-old male C57BL/6 mice received one intraperitoneal
injection of LPS 1 mg/g body weight (n=5 per group) and were
sacrificed 4 hours after injection. Hamp and Tmprss6 relative to
Rpl19 mRNA expression were analyzed by quantitative real-time
RT- PCR. Values shown are means of expression values divided
by a calibrator quantity (the mean value of expression for the
baseline group)+/2 SEM. Means in baseline and treated groups
were compared by student t tests. **p,0.01; ****p,0.001.
(TIF)
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